ResMed's cash cushion fell $458.49 M in a single quarter.
ResMed's cash cushion fell $458.49 M in one quarter, to $1.01 B from $1.47 B. The bigger shock is on the owners' side of the page. Shareholders' equity dropped $637.70 M, to $5.95 B, even though retained earnings, the profit kept over the years, still rose $323.46 M. The biggest single move is treasury stock, the shares ResMed bought back and holds, which rose $854.74 M in one quarter. Set against the $418.41 M of profit the quarter earned, that buyback was about twice as large.
Why buy back that much? The filing's explanation runs through the share count. ResMed repurchased 3.6 million shares for $855 million in the quarter. It also says it used part of the proceeds from selling its MatrixCare business to pay the $450 million due under an accelerated buyback agreement. The sale also lifts reported profit: its $62 million gain sits inside net income, while the $470 million of cash came in through investing, not through earnings. Inventory tells a different tale: finished goods rose $72.08 M in the quarter, and the filing says only that higher inventory levels are partially related to the expansion of its supply chain.
ResMed still has $2.51 B of cash and available credit, enough for its near-term bills on paper. The cushion is thinner now, and the $1.5 B revolving credit facility it can still draw on, undrawn today, terminates on June 29, 2027. Finished goods are the open question: they must sell through before they become cash, and the filing does not say how much of the build is planned stock. Will that stock turn into cash over the next few quarters, or come back as write-downs?

